期刊
CURRENT ONCOLOGY
卷 30, 期 6, 页码 5574-5592出版社
MDPI
DOI: 10.3390/curroncol30060421
关键词
hepatocellular carcinoma; HCC; immunosuppression; liver transplantation; mTOR; mTOR inhibitors
类别
Liver transplantation is an effective treatment option for nonresectable patients with early-stage HCC, especially when they meet the Milan criteria. However, the use of CNIs for immunosuppression increases the risk of tumor regrowth. mTOR inhibitors have emerged as an alternative immunosuppressive approach that can address both immunosuppression and cancer control. This review summarizes the roles of mTOR inhibitors in managing HCC patients undergoing LT and proposes strategies to overcome common adverse effects.
Liver transplantation is a treatment option for nonresectable patients with early-stage HCC, with more significant advantages when Milan criteria are fulfilled. An immunosuppressive regimen is required to reduce the risk of graft rejection after transplantation, and CNIs represent the drugs of choice in this setting. However, their inhibitory effect on T-cell activity accounts for a higher risk of tumour regrowth. mTOR inhibitors (mTORi) have been introduced as an alternative immunosuppressive approach to conventional CNI-based regimens to address both immunosuppression and cancer control. The PI3K-AKT-mTOR signalling pathway regulates protein translation, cell growth, and metabolism, and the pathway is frequently deregulated in human tumours. Several studies have suggested the role of mTORi in reducing HCC progression after LT, accounting for a lower recurrence rate. Furthermore, mTOR immunosuppression controls the renal damage associated with CNI exposure. Conversion to mTOR inhibitors is associated with stabilizing and recovering renal dysfunction, suggesting an essential renoprotective effect. Limitations in this therapeutic approach are related to their negative impact on lipid and glucose metabolism as well as on proteinuria development and wound healing. This review aims to summarize the roles of mTORi in managing patients with HCC undergoing LT. Strategies to overcome common adverse effects are also proposed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据